Semaglutide, a breakthrough medication, is not just limited to managing diabetes - it's now paving the way for innovative weight loss solutions. This FDA-approved compound mimics the action of a hormone called glucagon-like peptide-1 (GLP-1), which plays a crucial role in regulating food intake. By tapping into this natural mechanism, semaglutide helps control appetite and promotes weight loss. Administered as a subcutaneous injection, its transformative effects are evident in clinical trials, showcasing significant weight reduction and improved metabolic outcomes.
Tirzepatide, a cutting-edge medication, stands at the forefront of weight loss innovation. Distinct from traditional approaches, this FDA-approved compound targets multiple pathways involved in glucose and energy metabolism. By doing so, tirzepatide not only aids in reducing food intake but also improves glucose control. Administered through subcutaneous injection, it presents a groundbreaking solution for individuals seeking effective weight management.
When overweight, an individual increases their risks for high blood pressure, heart disease, diabetes, stroke, and some forms of cancer. If overweight, striving to lose 5 to 10% of your weight and maintaining that loss can and will lower the risks for developing most of these diseases.
Both compounded medications are glucagon-like peptide-1 (GLP-1) receptor agonist prescribed as an adjunct therapy to help effectively reduce appetite and enhance the body's ability to use fat while implementing a good exercise regimen and healthy diet.
Therapy is dependent on your current and past medical health history. Adults with a BMI of 27-29 (considered overweight) with at least one weight-related comorbidity such as hypertension or type 2 diabetes or adults with a BMI of 30 or greater (considered obese).
Weight-loss and other long term effects can be achieved when combining treatment and lifestyle modifications.
Both medications should be injected subcutaneously into upper arms, abdomen or thighs, alternating injection sites.
The most common side effects of Semaglutide and Tirzepatide include nausea, diarrhea/constipation, bloating, vomiting, and upset stomach. Symptoms usually subside overtime.
If there is a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MENS2) or in cases of hypersensitivity to either medication.
A skilled healthcare provider will conduct a comprehensive evaluation, to include but not limited to, blood work panel and an in-depth consultation, assessing your health and the appropriateness for therapy. Afterward, optimizing results will include adopting and following a healthy diet and exercise regimen.
Compounded Semaglutide and Tirzepatide are administered once a week via a subcutaneous injection. Weight loss should occur when therapy is administered, coupled with tailored lifestyle modifications that fit your needs.